Research Article

Antimicrobial Activity of *Saccharomyces cerevisiae* against *Candida* spp. Associated to Vulvovaginal Candidiasis

Djadouni Fatima[1,*], Boungab Karima[2]

[1]Department of Biology, Faculty of Natural Sciences and Life, Mascara University, Mascara, ALGERIA.
[2]Laboratory of Research on Biological Systems and Geomatics, Department of Agronomy, University of Mascara, Mascara, ALGERIA.

Submission Date: 20-11-2021; Revision Date: 28-11-2021; Accepted Date: 29-12-2021.

ABSTRACT

This research aims to study the antimicrobial activity (AMA) of *Saccharomyces cerevisiae* against *Candida* spp. associated to vulvovaginal candidiasis and compared their efficacy to other therapeutic alternatives. Clinical samples were collected from 70 women aged 40-50 years old, married with children and referred for chronic vulvovaginal complaints. Drug sensitivity test were carried out on 25 *Candida* isolates used disk diffusion method. Agar well diffusion method was used to evaluate the antifungal activity of vaginal douching solutions and the AMA of *S. cerevisiae*. Growth kinetic of antimicrobial agent was monitored by measuring optical density at 530 nm. Microdillution method was applied to determine MIC. In current study, *Candida* spp. distribution was (35.70%), Enterobacteriaceae (25.70%), *Staphylococcus* spp. (14.20%) and *Lactobacillus* spp. (14.20%). Identification of *Candida* isolates reveled that C. *albicans* was higher (52.0%) then *C. glabrata* (36.0%) and *C. tropicalis* (12.0%). Drug susceptibility testing showed that *C. albicans* YCI13, *C. grabrata* YCI15, *C. tropicalis* YCI23 and *C. tropicalis* YCI25 were high resistant to antibiotics and resist relatively to antifungals. *Candida* spp. were resistant to citric acid, acetic acid and H_2O_2, but sensible to $NaHCO_3$ and EDTA. *S. cerevisiae* showed effective antifungal activity against *C. albicans* YCI13, *C. grabrata* YCI15, *C. tropicalis* YCI23 and *C. tropicalis* YCI25. The AMA peaked at the early latency phase and high level was produced during exponential phase 24 h of fermentation. MIC and MBC values of *S. cerevisiae* antimicrobial agent are 0.25 µg / ml and 3.10^4 cfu / ml against *C. tropicalis* YCI25. The study concluded that we can formulate a novel antifungal agent of natural origin from *S. cerevisiae* which could be used as a cheaper alternative for the therapeutic management of vulvovaginal candidiasis.

Key words: Candidiasis, *Candida* spp., Drugs resistance, Antiseptics, *Saccharomyces cerevisiae*, Antimicrobial activity.

Correspondence:
Dr. Djadouni Fatima
Biology Department, Faculty of Natural Sciences and Life, Mascara University, Mascara 29000, ALGERIA.

Email: sdjadouni@gmail.com
ORCID: 0000-0002-0689-2244

INTRODUCTION

Candida is a microscopic fungus that is usually harmless and found in the genital tract, digestive tract, mouth, and on the skin. It can sometimes become pathogenic by releasing toxins.[1,2] Candidiasis is a disease caused by the fungi *Candida*, and it is spread especially in hot and humid places.[3]

Vulvovaginal candidiasis is among the most common human mycoses causing significant gynaecological and obstetric morbidity.[4] Studies have found that this affection accounted for 75% of all infections vaginal in women. 95% of cases are result of *C. albicans* and incidence rate of non-*C. albicans* is 5%.[5,6]

Some factors favor the appearance of this condition including antibiotics use, long term steroid treatment, sexual intercourse, diabetes mellitus, immunosupression, pregnancy, and cunnilingus, use of vaginal contraceptive

SCAN QR CODE TO VIEW ONLINE

www.ajbls.com

DOI: 10.5530/ajbls.2022.11.9

sponges and intrauterine device, and miscellaneous factors.[7]

Women with vulvitis caused by VVC may respond best to a combination of intravaginal and topical vulval therapy. Conventional antifungal Imidazole, Triazole, Polyene, and Nystatin agents are used to treat VVC. Non- *albicans Candida* spp. infection was treated with Amphotericin, Flucytosine, Boric acid and Crystal violet (gentian), depending on the susceptibility profile of the isolates.[8,9]

Increasing incidence of antifungal resistance over time lead to research for other alternatives as natural derivatives with antifungal properties from plants extracts, animals products and microbial substances.[10,11] *S. cerevisiae* is unicellular microscopic yeast widely distributed in the natural environment, it belonging to *Saccharomycetaceae* family and used in industrial applications, genetic studies, and clinical researchs. Many studies showed that *Saccharomyces* genus characterized by angonistic properties and probiotic with various health promoting benefits.[12,13] Therefore, the objective of this study was to evaluate the antimicrobial activity of *S. cerevisiae* against *Candida* species associated to VVC and compared their efficacy to other therapeutic alternatives such as standard antibiotics, antiseptics, and vaginal douching solutions.

MATERIALS AND METHODS

Vaginal swabs collection

Clinical samples were collected from 70 women aged 40-50 years old, married with children and referred for chronic vulvovaginal complaints to Hospital-Maternity Service of Mascara, Algeria during 2018. Vaginal secretions were collected using a moisten swab with sterile saline (0.9% NaCl, Institute Pasteur, Algeria). The samples were transferred to the laboratory for study.[14]

Isolation and identification of microbial strains

Brain heart broth (BHI, Merck, Germany) was used as an enrichment medium for all bacterial strains. Several selective media (Merck, Germany) were used for isolation and purification of cultures including Chapman Agar for *Staphylococcus* spp., Salmonella-Shigella Agar (SS), Hektoen Agar and Eosine Blue Methylene Agar for Enterobacteriaceae. MRS agar (De Man Rogosa and Sharpe Agar) for *Lactobacillus* spp.,[15] Yeast Potato Dextrose Agar (YPD) and Sabouraud Agar for *Candida* spp.[16,17] Clinical yeast isolates were identified through morphological, cultural, physiological and biochemical tests in Medical Laboratory of Hospital-Maternity Service of Mascara, Algeria. Identification of the bacterial strains was carried out by Gram staining followed by conventional biochemical tests.[18]

Candida spp. drug susceptibility test

A total of 63 recent clinical isolates (bacteria and yeast) were isolated from the vaginal discharge samples. Drug sensitivity test were carried out on 25 *Candida* isolates and by disk diffusion method on Muller Hinton Agar plates (MH, Merck, Germany) in the presence of selected antibiotics divided into four (04) antifungal that are active against a VVC infections and include Metronidazole 500 mg, Neomycin Sulfate 65000 UI, Nystatin 100000 UI, and Polymyxin Sulfate 35000 UI, and four (04) antibacterial antibiotics include Piperacillin 75 µg, Streptomycin 10 µg, Cloxacillin 5 µg, and Trimethoprim 5 µg. MH agar plates are inoculated with yeast inoculum 1.5×10^8 cfu / ml (0.5 Mc Farland) and incubated for 16–24 h at 35°C and then the diameters of inhibition growth zones are measured and results were compared to CLSI standard documents.[19,20]

Antifungal activity of vaginal douching on *Candida* spp.

5% acetic acid, 5% citric acid, 1 gr/ 10 ml sodium bicarbonate $NaHCO_3$, 1 ml/ 10 ml disodium EDTA and 1 ml/ 10 ml hydrogen peroxide H_2O_2 were dissolved in distilled water (v/v) and sterilized by Millipores 0.22 µm filter (Millex-GV, Renner D-67125/GMBH Germany) to eliminate contamination. Evaluation of antifungal activity is performed using agar well diffusion method. Agar plate surface is inoculated by spreading the yeast inoculum (1.5×10^8 cfu/ ml) over the entire agar surface. 100 µl of each antifungal solution is introduced into wells (5 mm in diameter) and plates were first placed at 4°C for 30 min in order to diffusion of antifungal and then incubated for 16-24 h at 35°C. After incubation, the antimicrobial interactions are analyzed by observing the inhibition zone size.[21,22]

Antimicrobial activity of *S. cerevisiae*

Inoculum preparation and cultural conditions

S. cerevisiae was taken from the Commercial Baker Yeast (Pakmaya, SARL VITA ferme, Elharrach- Alger, 2018). The yeast strain was characterized based on their cultural characteristics (Colony shapes, pigment, elevation, edge and surface appearance). Morphological and biochemical characterization of the isolated yeast was performed according to Boboye and Dayo-Owoyemi.[23]

Antimicrobial spectrum

Inhibitory activity of *S. cerevisiae* against the high resistant *Candida* spp. was assayed by the agar well diffusion assay. The cells of *S. cerevisiae* were grown as 2% in YPD broth at 30°C, collected after 24 hr at early exponential phase by centrifugation at 10,000 xg for 20 min at 4°C. The cell supernatant CS was passed through membrane filters with a pore diameter of 0.22 µm to eliminate contamination and stored in the refrigerator at 4°C until use. A volume of 100 µl of CS is induced into wells, after incubation the diameters of inhibition zones were scored in mm.[24,25]

Detection of antimicrobial agent production during growth kinetic

Test strain *S. cerevisiae* (1.5×10^8 cfu / ml, 2% v/v) is cultivated into 100 ml of YPD broth and incubated at 30°C for 24 h. Growth is evaluated every 2 hr on basis of 530 nm turbidimetry measurements. Then, cells were removed from the broth culture by centrifugation at 10,000 xg for 20 min at 4°C Avery 2 h. Pathogen indicator strain *C. tropicalis* YCI25 (1.5×10^8 cfu / ml) was added to the culture supernatant CS and incubated at 35 °C for 16-24 h. Percentage of inhibition was expressed as inhibition (%) of indicator strain growth relative to the control (*C. tropicalis* YCI25 cultevated in YPD broth without CS).[26]

Evaluation of antifungal activity by broth microdilution

For quantitative tests to determine MIC, serial dilutions from culture supernatant CS (taken in the exponential phase growth 24 h) were made with MH broth. 100 µl of CS was added in each well of 96-well microtiter plate and inoculated with 100 µl of the diluted suspension of *C. tropicalis* YCI25. For each test plate, two controls were included, one with the medium alone (sterile control) and the other with 100 µl of medium plus 100 µl of inoculum suspension (growth control). The microdilution plates were incubated at 35°C and were read visually after 24 h of incubation. Sample well producing negative microbial growth was inoculated by spreading on YPD plate surface and incubated at 35°C for 24 h to determine the minimum bactericidal concentration MBC in cfu/ ml.[24,27]

Statistical analysis

The experiments were repeated three times and data were expressed as mean ± standard deviation.

RESULTS

Distribution of vaginal discharge isolates

Results show the high rate of *Candida* spp. (35.70%), followed by Enterobacteriaceae (25.70%), then *Staphylococcus* spp. (14.20%), and *Lactobacillus* spp. (14.20%), Figure 1.

Gram staining and phenotypic characteristics findings of 25 *Candida* isolates on Sabouraud Dextrose Agar and Chrome Agar showed that *C. albicans* (Figure 2) was higher distrubition (52.0%) then *C. glabrata* (36.0%) and *C. tropicalis* (12.0%). Results were shown in Table 1.

Antibiotics susceptibility

The results of the antibiotics were shown in Tables 2 and 3. Interpretation criteria were determined following the CLSI standards.[28,29] All *Candida* spp. were resistant to Piperacillin, Sreptomycin, Cloxacillin, Trimethoprim, whereas *C. albicans* showed a resistant inferior to Metronidazole 23.07%, Neomycin Sulfate 38.40%, Nystatin 15.30 %, and Polymyxin Sulfate 23.07%. Resistance of *C. grabrata* to these antifungal



Figure 1: Percentage of vaginal discharge isolates.



Figure 2: Methylene blue staining of *C. albicans*. Blastese test : TG : germinative tube/ CC : Corps cellulaire/ CH: Chlamydospore/ PM: Pseudomycelium/ BS: Blaspospore.

Table 1: Percentage of distribution and some morphological, phenotypic and virulence characteristics of Candida species isolated from vaginal discharge samples.

Candida isolates	Species and distrubition %	Color on Sabouraud agar	Color on Chrome agar	Germ Tube Test	Growth at 45°C	Chlamydospores	Growth at 30°C and 35°C
YCI1	52.0% *C. albicans*	Creamy	Light green	+	+	+	+
YCI2		Creamy	Light green	+	+	+	+
YCI3		Creamy	Light green	+	+	+	+
YCI4		Creamy	Light green	+	+	+	+
YCI5		Creamy	Light green	+	+	+	+
YCI6		Creamy	Light green	+	+	+	+
YCI7		Creamy	Light green	+	+	+	+
YCI8		Creamy	Light green	+	+	+	+
YCI9		Creamy	Light green	+	+	+	+
YCI10		Creamy	Light green	+	+	+	+
YCI11		Creamy	Light green	+	+	+	+
YCI12		Creamy	Light green	+	+	+	+
YCI13		Creamy	Light green	+	+	+	+
YCI14	36.0% *C. glabrata*	Creamy	White Ppurple/pink	-	-	-	+
YCI15		Creamy	White Ppurple/pink	-	-	-	+
YCI16		Creamy	White Ppurple/pink	-	-	-	+
YCI17		Creamy	White Ppurple/pink	-	-	-	+
YCI18		Creamy	White Ppurple/pink	-	-	-	+
YCI19		Creamy	White Ppurple/pink	-	-	-	+
YCI20		Creamy	White Ppurple/pink	-	-	-	+
YCI21		Creamy	White Ppurple/pink	-	-	-	+
YCI22		Creamy	White Ppurple/pink	-	-	-	+
YCI23	12.0% *C. tropicalis*	Creamy	Metalic blue	-	-	-	+
YCI24		Creamy	Metalic blue	-	-	-	+
YCI25		Creamy	Metalic blue	-	-	-	+

was lower 11.11% to 33.33%, but *C. tropicalis* showed relative resistance superior of 66.0%. Four isolates *C. albicans* YCI13, *C. grabrata* YCI15, *C. tropicalis* YCI23, and *C. tropicalis* YCI25 were high resistant to both antibacterials and antifungals respectively.

As shown in Table 4, in antifungal susceptibility testing using five vaginal douching solutions, the four *Candida* species were sensible to disodium EDTA with average diameter inhibition zone ranged between 22.0 mm and 26.0 mm. In addition, *C. albicans* YCI13 and *C. tropicalis* YCI23 were sensible to sodium bicarbonate with diameter inhibition zone 15.0 mm and 22.0 mm respectively, but *C. glabrata* YCI15 and *C. tropicalis* YCI25 were resistant. Whereas, acetic acid sensibility was observed in *C. tropicalis* YCI25 (15.0 mm) and the rest species were more resistant. Citric acid, acetic acid and H_2O_2 resistance was observed against all strains in compared with sodium bicarbonate and sodium EDTA.

Antimicrobial activity of *S. cerevisiae*

Antifungal effect of *S. cerevisiae* was better against *C. tropicalis* YCI23 and YCI25 with diameter inhibition zone 10 to 17 mm than *C. albicans* YCI13 06 mm and *C. glabrata* YCI15 08 mm. Culture supernatant showed least antifungal activity compared to disodium EDTA and standard antifungal drugs (Figure 3 and 4).

Table 2: Antibiotic susceptibility and screening of resistant *Candida* species.

Candida isolates	Pi 75 µg	Str 10µg	Cl 5µg	Tri 5µg	M 500mg	NS 65000UI	Nys 100000UI	PS 35000UI
YCI1	NZ R	NZ R	NZ R	NZ R	13.0 I	NZ R	13.0 I	15.0 S
YCI2	NZ R	NZ R	NZ R	NZ R	12.0 I	12.0 I	11.0 I	12.0 I
YCI3	NZ R	NZ R	NZ R	NZ R	NZ R	17.0 I	15.0 S	16.0 I
YCI4	NZ R	NZ R	NZ R	NZ R	15.0 I	NZ R	15.0 S	16.0 S
YCI5	NZ R	NZ R	NZ R	NZ R	13.0 I	32.0 S	10.0 I	18.0 I
YCI6	NZ R	NZ R	NZ R	NZ R	23.0 S	26.0 S	18.0 S	15.0 I
YCI7	NZ R	NZ R	NZ R	NZ R	15 I	NZ R	14.0 I	16.0 I
YCI8	NZ R	NZ R	NZ R	NZ R	NZ R	12.0 I	10.0 I	NZ R
YCI9	NZ R	NZ R	NZ R	NZ R	12.0 I	22.0 S	NZ R	14.0 I
YCI10	NZ R	NZ R	NZ R	NZ R	19.0 I	NZ R	13.0 I	NZ R
YCI11	NZ R	NZ R	NZ R	NZ R	16.0 I	11.0 I	10.0 I	11.0 I
YCI12	NZ R	NZ R	NZ R	NZ R	16.0 I	25.0 S	18.0 S	17.0 I
YCI13*	NZ R	NZ R	NZ R	NZ R	NZ R	NZ R	NZ R	NZ R
YCI14	NZ R	NZ R	NZ R	NZ R	16.0 I	15.0 I	14.0 I	12.0 I
YCI15*	NZ R	NZ R	NZ R	NZ R	NZ R	NZ R	NZ R	NZ R
YCI16	NZ R	NZ R	NZ R	NZ R	16.0 I	17.0 I	14.0 I	10.0 I
YCI17	NZ R	NZ R	NZ R	NZ R	15.0 I	15.0 I	17.0 S	15.0 S
YCI18	NZ R	NZ R	NZ R	NZ R	20.0 S	NZ R	23.0 S	NZ R
YCI19	NZ R	NZ R	NZ R	NZ R	17.0 I	20.0 S	18.0 S	22.0 S
YCI20	NZ R	NZ R	NZ R	NZ R	30.0 S	NZ R	23.0 S	17.0 S
YCI21	NZ R	NZ R	NZ R	NZ R	20.0 S	18.0 I	17.0 S	NZ R
YCI22	NZ R	NZ R	NZ R	NZ R	NZ R	18.0 I	19.0 S	15.0 I
YCI23*	NZ R	NZ R	NZ R	NZ R	NZ R	NZ R	NZ R	NZ R
YCI24	NZ R	NZ R	NZ R	NZ R	12.0I	15.0 I	15.0 S	13.0 I
YCI25*	NZ R	NZ R	NZ R	NZ R	NZ R	NZ R	NZ R	NZ R

Legends: YCI: yeast Candida isolate, R: resistant, S: sensitive, I: intermediate. NZ: no zone, Pi: Piperacillin 75µg, Str: Streptomycin 10µg, Cl: Cloxacillin 5µg, Tr: Trimethoprim 5µg, M: Metronidazole 500mg, NS: Neomycin Sulfate 65000UI, Nys: Nystatin 100000UI, PS: Polymyxin Sulfate 35000UI, *: *Candida* species high resistant to all antibiotics. The zones diameter of growth inhibition was in mm.



Figure 3: Antifungal activity of *S. cerevisiae* against *Candida* species.



Figure 4: Inhibition zone of *S. cerevisiae* CFS activity against *Candida* spp. performed on YPD agar using well diffusion method.

Detection of antimicrobial agent derived by *S. cerevisiae* during growth

High antimicrobial agent was recorded during the latency phase at zero time to 10 h and the *S cerevisiae* biomass amount was OD 0.668. Figure 5 depicts high antifungal activity against *C. tropicalis* YCI25 yeast at zero time, and maximal antifungal activity was achieved at the exponential phase for 24 h. The biomass concentration was OD 0.870 at this phase (Figure 5).

MIC and MBC of *S. cerevisiae* antimicrobial agent

MIC is 0.25 µg/ ml and MBC is 3.10^4 cfu/ ml for *C. tropicalis* YCI25 that shows a significant sensibility (Figure 6).



Figure 5: Optical density (OD) of *S. cerevisiae* in the antimicrobial test against *C. tropicalis* YCI25 performed with YPD broth.



Figure 6: MIC and MBC values of cell supernatant of against *S. cerevisiae* against *C. tropicalis* YCI25.

DISCUSSION

In this study, 25 yeasts were isolated from 70 fluid vaginal samples (35.70 %) of womens referred for chronic vulvovaginal complaints and this frequency was consistent with previously published data.[28,29] In previous study, it was found that *Candida* spp. is the most common germ causing infection in married and pregnant women, as well as elderly women and those with chronic diseases. As for bacterial vaginosis, enterobacteriaceae are showed in a few cases and are caused by poor hygiene and genital practices.[30] Many research papers show that VVC is an infectious disease transmitted to women, especially when their sexual activity increases and affects about 70 to 75% of women in reproductive age.[31,32] Our results are consistent with many studies that have been shown that incidence of bacterial vaginosis occurs in non-pregnant women (30.76%) and women with childbearing age (30.0%), whereas candidiasis was more common in pregnant women (61.53%).[33] Present of pathogens in high concentration in the vagina is the result of the decrease of protective resident microorganisms (Doderlein Flora) as *Lactobacillus* spp. (14.20%), which is in normal condition 90.0 to 95.0%. Lactobacilli were present at a low relative abundance in women that have bacterial vaginosis infections and become opportunistic pathogens when the normal vaginal microflora was imbalance.[34-36]

Table 3: Percentage % of resistant *Candida* species to antibiotics.

Candida isolates	Pi75 µg	Str 10µg	Cl 5µg	Tri 5µg	M 500mg	NS 65000UI	Nys 100000UI	PS 35000UI
C. albicans	100	100	100	100	23.07	38.40	15.30	23.07
C. glabrata	100	100	100	100	22.22	33.33	11.11	33.33
C. tropicalis	100	100	100	100	66.66	66.66	66.66	66.66

Legends: YCI: yeast *Candida* isolate, Pi: Piperacillin 75µg, Str: Streptomycin 10µg, Cl: Cloxacillin 5µg, Tr: Trimethoprim 5µg, M: Metronidazole 500mg, NS: Neomycin Sulfate 65000UI, Nys: Nystatin 100000UI, PS: Polymyxin Sulfate 35000UI.

Table 4: Antimicrobial activity of vaginal douching solutions against *Candida* species.

Candida species	Acetic acid 5%	Citric acid 5%	Sodium bicarbonate	Hydrogen peroxide	Disodium EDTA
			Inhibition diameter zone mm*		
C. albicans YCI13	04.0 R	00.0 R	15.0 S	00.0 R	22.0 S
C. glabrata YCI15	06.0 R	00.0 R	10.0 R	00.0 R	26.0 S
C. tropicalis YCI23	08.0 R	08.0 R	22.0 S	08.0 R	25.0 S
C. tropicalis YCI25	15.0 S	10.0 R	00.0 R	10.0 R	26.0 S

Legends: R: resistant, S: sensitive, I: intermediate.

According to many research, some symptoms were seen during diagnosis as vaginal discharge, pruritus, and burning sensation. The vaginal infections is associated with several factors as site, age of the patient and hormonal background (circulating oestrogen levels), pregnancy, phase of menstrual cycle, and use of oral contraceptive device, sexual contact, shared bathrooms, and hygiene behaviors.[37-39] *Candida* species are most frequently isolated from the vulvovaginal and are detected in approximately 31–55% of healthy individuals.[40,41] In our study, the overall prevalence of *C. albicans* was found to be 52.0%, *C. albicans* is considered as a vaginal mycoflora and the main causative agent of vaginal candidiasis, non-albicans species have increased during last decades.[42,43] Several authors have believed that 75% of women are affected at least once during lifetime. Furthermore, chronic vaginitis and recurrent VVC were more reported among several groups of women; both forms of diseases are problematic conditions for patients. The healthy women vagina is containing several normal microflora including *C. albicans*, and patients associated factors (patient physiology, hormone balance, and decrease in immune function), organism pathogenic factors, and external factors are interference in involving disease.[44,45] *C. albicans* is the most prevalent species isolated from the stools of women with candidiasis, while the ratio of non-*albicans Candida* spp. is increasing over the past several years, such as *C. glabrata*, *C. tropicalis*, *C. parapsilosis,* and *C. krusei*. Azoles, polyenes, echinocandins, and allylamines are major classes of available antifungals against fungal infection in human. Growing fungal resistance, however, limits their favorable therapeutic efficacies, ultimately making the treatment of fungal infection disease more intractable. Effective strategies to cope with fungal resistance issues are therefore urgently needed.[46,47] Recently, some researchers have been dedicating to searching for non-antifungals that can enhance the efficacy of conventional antifungals against *Candida* spp. such as antibiotics. Interestingly, researchers found that some of them displayed potential antifungal activities when used alone or in combination with antifungals but there are a series of reports regarding that antibiotics have become ineffective in treating the VVC, especially if they are used for treatment for a long time, as the germs become more resistant to these drugs, especially when the patients suffer from other diseases.[48,49] On the basis of various research papers, the chelator sodium EDTA shows a high effectiveness as anticandidiasis, but it use for long time lead to the imbalance in the vaginal microbiota and irritation of vagina.[50] Chemicals vaginal solutions as citric acid, acetic acid, H_2O_2 and $NaHCO_3$ showed a significant inhibitory effect against *Candida* spp. when they are mixed with others antiseptics ingredients such as purified water, diazolidinyl urea, sodium citrate, vinegar, octoxynol-9, benzoic acid, edetate disodium, and lysol. But water mixed with vinegar give good result and is harmless for vagina and Doderlein Flora.[51,52] Although vaginal douching is effective, according to many studies, it has side effects, among them inflammation, risk reproductive tract infections, and remove normal vaginal flora.[53] Many studies reported that *S. cerevisiae* possesses antagonistic activity against other yeasts and microbial pathogens negative and positive bacteria.[54,55] According to some data,[56] yeast produces a large range of secondary metabolites as killer toxins (mycocins), organic acids, antibiotic factors, volatile acids, and hydrogen peroxide which support the inhibitory mechanisms. The antagonistic properties of *S. cerevisiae* enabled in the medical field, food and feed, agriculture, veterinary medicine and environmental protection.[57,58] According to previously published data, *S. cerevisiae* produce high level of antimicrobial agent in the end of the exponential growth phase, and those compounds are peptides of 2-10 kDa that are active against several yeasts and bacteria such as *Dekkera bruxellensis*, *Kluyveromyces marxianus*, *Lachancea thermotolerans*, *Torulaspora delbrueckii*, and *Hanseniaspora guilliermondii* and bacteria (e.g., *Oenococcus oeni*).[54,58,59] However, the MIC of *S. cerevisiae* antimicrobial agent is 0.25 µg/ ml and MBC is 3.104 cfu/ ml against *C. tropicalis* YCI25. Consequently, it considered as a promising potential new antifungal drug.[60,61]

CONCLUSION

S. cerevisiae 0.25 µg/ml has shown promising antimicrobial activity and a broad spectrum of action against infectious and virulent *Candida* spp. It is considered an alternative antimicrobial agent in treatment VVC and the field medicine.

ACKNOWLEDGEMENT

We would like to thank Mss Bouziane Karima, Doctor Gynecologist in Deriex Health Center of Mascara (Algeria) for their help in the isolation of microbial strains from women with candidiasis.

CONFLICT OF INTEREST

The authors declare that there is no conflict of interest.

ABBREVIATIONS

AMA: Antimicrobial Activity; **CFU:** Colony-forming Unit; **CLSI:** Clinical and Laboratory Standards Institute; **IU:** International Unit; **KDa:** Kilodaltons; **MIC:** Minimum Inhibitory Concentration; **OD:** Optical Density; **VVC:** Vulvovaginal Candidiasis.

SUMMARY

The study concluded that we can formulate a novel antifungal agent of natural origin from *S. cerevisiae* which could be used as a cheaper alternative for the therapeutic management of vulvovaginal candidiasis in womens.

REFERENCES

1. Sardi JCO, Scorzoni L, Bernardi T, Fusco-Almeida AM, Mendes Giannini MJS. Candida species: Current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options. J Med Microbiol. 2013;62(1):10-24. doi: 10.1099/jmm.0.045054-0, PMID 23180477.
2. Ilkit M, Guzel AB. The epidemiology, pathogenesis, and diagnosis of vulvovaginal candidosis: A mycological perspective. Crit Rev Microbiol. 2011;37(3):250-61. doi: 10.3109/1040841X.2011.576332, PMID 21599498.
3. Metin A, Dilek N, Bilgili SG. Recurrent candidal intertrigo: Challenges and solutions. Clin Cosmet Investig Dermatol. 2018;11:175-85. doi: 10.2147/CCID.S127841, PMID 29713190.
4. Nwadioha SI, Egah DZ, Alao OO. Risk factors for vag¬inal candidiasis among women attending primary health care centers of Jos, Nigeria. J Clin Med Res. 2010;2(7):110-3.
5. Silva S, Negri M, Henriques M, Oliveira R, Williams DW, Azeredo J. Candida glabrata, Candida parapsilosis and Candida tropicalis: Biology, epidemiology, pathogenicity and antifungal resistance. FEMS Microbiol Rev. 2012;36(2):288-305. doi: 10.1111/j.1574-6976.2011.00278.x, PMID 21569057.
6. Ravel J, Gajer P, Abdo Z, Schneider GM, Koenig SSK, McCulle SL, Karlebach S, Gorle R, Russell J, Tacket CO, Brotman RM, Davis CC, Ault K, Peralta L, Forney LJ. Vaginal microbiome of reproductive-age women. Proc Natl Acad Sci U S A. 2011;108;Suppl 1:4680-7. doi: 10.1073/pnas.1002611107, PMID 20534435.
7. Balamurugan S, Bendigeri N. Community-based study of reproductive tract infections among women of the reproductive age group in the urban health training centre area in Hubli, Karnataka. Indian J Community Med. 2012;37(1). doi: 10.4103/0970-0218.94020.
8. da Fonseca TM MV, Cesar J A, Mendoza-Sassi R A, Schmidt E B. Pathological vaginal discharge among pregnant women: Pattern of occurrence and association in a population-based survey. Obstet. Gynecol. Int. 2013; 7. doi: 10.1155/2013/590416, PMID: 23843798.
9. Richter SS, Galask RP, Messer SA, Hollis RJ, Diekema DJ, Pfaller MA. Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases. J Clin Microbiol. 2005;43(5):2155-62. doi: 10.1128/JCM.43.5.2155-2162.2005, PMID 15872235.
10. Mishra NN, Prasad T, Sharma N, Payasi A, Prasad R, Gupta DK, Singh R. Pathogenicity and drug resistance in Candida albicans and other yeast species. A review. Acta Microbiol Immunol Hung. 2007;54(3):201-35. doi: 10.1556/AMicr.54.2007.3.1, PMID 17896473.
11. Bitew A, Abebaw Y. Vulvovaginal candidiasis: Species distribution of Candida and their antifungal susceptibility pattern. BMC Womens Health. 2018;18(1):94. doi: 10.1186/s12905-018-0607-z, PMID 29902998.
12. Kelesidis T, Pothoulakis C. Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders. Therap Adv Gastroenterol. 2012;5(2):111-25. doi: 10.1177/1756283X11428502, PMID 22423260.
13. Fakruddin MD, Hossain MN, Ahmed MM. Antimicrobial and antioxidant activities of *Saccharomyces cerevisiae* IFST062013, a potential probiotic. BMC Complement Altern Med. 2017;17(1):64. doi: 10.1186/s12906-017-1591-9, PMID 28109187.
14. Hasanvand S, Azadegan Qomi H, Kord M, Didehdar M. Molecular epidemiology and *in vitro* antifungal susceptibility of Candida isolates from women with vulvovaginal candidiasis in Northern Cities of Khuzestan Province, Iran. Jundishapur J Microbiol. 2017;10(8):e12804. doi: 10.5812/jjm.12804.
15. Pendharkar S, Magopane T, Larsson PGR, de Bruyn G, Gray GE, Hammarström LH, Marcotte H. Identification and characterisation of vaginal lactobacilli from South African women. BMC Infect Dis. 2013;13:43. doi: 10.1186/1471-2334-13-43, PMID 23351177.
16. Hedayati MT, Taheri Z, Galinimoghadam T, Aghili SR, Yazdani Cherati J, Mosayebi E. Isolation of different species of Candida in patients with vulvovaginal candidiasis from sari, iran. Jundishapur J Microbiol. 2015;8(4):e15992. doi: 10.5812/jjm.8(4)2015.15992. PMID 26034533.
17. Madhavan P, Jamal F, Chong PP. Laboratory isolation and identification of Candida species. J Appl Sci. 2011;11(16):2870-7. doi: 10.3923/jas.2011.2870.2877.
18. Garrity GM, Brenner DI, Krieg ER, Stanley JT. Bergey's manual of systemic bacteriology. 2nd ed. New York: Springer-Verlag; 2005; 2.
19. Khan EI, Kamal RS, Ullah H. Anxiolytic effect of midazolam premedication assessed by clinical and platelet aggregation profiles. J Ayub Med Coll Abbottabad. 2010;22(2):4-7. PMID 21702254.
20. Clinical and Laboratory Standards Institute. Method for antifungal disk diffusion susceptibility testing of yeasts: Approved guideline. Wayne, PA: Clinical and Laboratory Standards Institute; 2004.
21. Pavlova SI, Tao L. *In vitro* inhibition of commercial douche products against vaginal microflora. Infect Dis Obstet Gynecol. 2000;8(2):99-104. doi: 10.1002/(SICI)1098-0997(2000)8:2<99::AID-IDOG7>3.0.CO;2-N.
22. Reference method for broth dilution antifungal susceptibility testing of yeasts. 3rd ed; 2008.
23. Boboye B, Dayo-Owoye I. Evaluation of dough sensory properties impacted by yeasts isolated from Cassava. J Appl Sci. 2009;9(4):771-6. doi: 10.3923/jas.2009.771.776.
24. Balouiri M, Sadiki M, Ibnsouda SK. Methods for *in vitro* evaluating antimicrobial activity: a review. J Pharm Anal. 2016;6(2):71-9. doi: 10.1016/j.jpha.2015.11.005, PMID 29403965.
25. National Committee For Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard M38-A. Wayne, PA; 2002.
26. Albergaria H, Francisco D, Gori K, Arneborg N, Gírio F. *Saccharomyces cerevisiae* CCMI 885 secretes peptides that inhibit the growth of some non-Saccharomyces wine-related strains. Appl Microbiol Biotechnol. 2010;86(3):965-72. doi: 10.1007/s00253-009-2409-6, PMID 20039034.
27. Murray CK, Hospenthal DR. Broth microdilution susceptibility testing for Leptospira spp. Antimicrob Agents Chemother. 2004;48(5):1548-52. doi: 10.1128/AAC.48.5.1548-1552.2004, PMID 15105104.
28. Waikhom SD, Afeke I, Kwawu GS, Mbroh HK, Osei GY, Louis B, Deku JG, Kasu ES, Mensah P, Agede CY, Dodoo C, Asiamah EA, Tampuori J, Korbuvi J, Opintan JA. HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/32375724/" Prevalence of vulvovaginal candidiasis among pregnant women in the Ho municipality, Ghana: species identification and antifungal susceptibility of Candida isolates. BMC Pregnancy Childbirth. 2020; 6, 20(1):266. doi: 10.1186/s12884-020-02963-3, PMID 32375724
29. Mitchell H. Vaginal discharge--causes, diagnosis, and treatment. BMJ. 2004;328(7451):1306-8. doi: 10.1136/bmj.328.7451.1306, PMID 15166070.
30. Turovskiy Y, Sutyak Noll K, Chikindas ML. The aetiology of bacterial vaginosis. J Appl Microbiol. 2011;110(5):1105-28. doi: 10.1111/j.1365-2672.2011.04977.x, PMID 21332897.
31. Mahmoudi Rad M, Zafarghandi ASh, Amel Zabihi MA, Tavallaee M, Mirdamadi Y. Identification of Candida species associated with vulvovaginal candidiasis by multiplex PCR. Infect Dis Obstet Gynecol. 2012;2012:872169. doi: 10.1155/2012/872169, PMID 22791958.
32. Twinkle NG, Manish GP, Mannu R. Prospective study of vaginal discharge and prevalence of vulvovaginal candidiasis in a tertiary care hospital. Int J Curr Res Rev. 2015;7(1):34-8.

33. Mahmoudi Rad M, Zafarghandi S, Abbasabadi B, Tavallaee M. The epidemiology of Candida species associated with vulvovaginal candidiasis in an Iranian patient population. Eur J Obstet Gynecol Reprod Biol. 2011;155(2):199-203. doi: 10.1016/j.ejogrb.2010.11.022, PMID 21194828.
34. Yadav K, Prakash S. Prevalence of vulvovaginal candidiasis in pregnancy. Glob. J. Med. Med Sci. 2016;4(1):108-16.
35. Verdenelli MC, Coman MM, Cecchini C, Silvi S, Orpianesi C, Cresci A. Evaluation of antipathogenic activity and adherence properties of human Lactobacillus strains for vaginal formulations. J Appl Microbiol. 2014;116(5):1297-307. doi: 10.1111/jam.12459, PMID 24552173.
36. Mendes-Soares H, Suzuki H, Hickey RJ, Forney LJ. Comparative functional genomics of Lactobacillus spp. reveals possible mechanisms for specialization of vaginal lactobacilli to their environment. J Bacteriol. 2014;196(7):1458-70. doi: 10.1128/JB.01439-13, PMID 24488312.
37. Konaté A, Yavo W, Kassi FK, Djohan V, Angora EK, Barro-Kiki PC, Bosson-Vanga H, Soro F, Menan EI. Aetiologies and contributing factors of vulvovaginal candidiasis in Abidjan (Cote d'Ivoire). J Mycol Med. 2014;24(2):93-9. doi: 10.1016/j.mycmed.2013.11.006. PMID 24387809.
38. Edwards JE. Candida species. In: principles and practice of infectious diseases Bennett JE, Dolin R, Blaser MJ, editors. 8th ed. Amsterdam, The Netherlands: Elsevier; 2015. p. 2879-94.
39. Kalia N, Singh J, Sharma S, Arora H, Kaur M. Genetic and phenotypic screening of mannose-binding lectin in relation to risk of recurrent vulvovaginal infections in women of North India: A prospective cohort study. Front Microbiol. 2017;8(75):75. doi: 10.3389/fmicb.2017.00075, PMID 28197138.
40. Mohanty S, Xess I, Hasan F, Kapil A, Mittal S, Tolosa JE. Prevalence and susceptibility to fluconazole of Candida species causing vulvovaginitis. Indian J Med Res. 2007;126(3):216-9. PMID 18037716.
41. Fan SR, Liu XP, Li JW. Clinical characteristics of vulvovaginal candidiasis and antifungal susceptibilities of Candida species isolates among patients in southern China from 2003 to 2006. J Obstet Gynaecol Res. 2008;34(4):561-6. doi: 10.1111/j.1447-0756.2008.00817.x, PMID 18937710.
42. Zarei Mahmoudabadi A, Najafyan M, Alidadi M. Clinical study of Candida vaginitis in Ahvaz, Iran and susceptibility of agents to topical antifungal. Pak J Med Sci. 2010;26(3):607-10.
43. Al-Oebady MAH. Isolation and identification of Candida species from vaginal, urine and oral swabs by chromagar Candida. Int J Adv Res. 2015;3(1):948-56.
44. Rezaei-Matehkolaei A, Shafiei S, Zarei-Mahmoudabadi A. Isolation, molecular identification, and antifungal susceptibility profiles of vaginal isolates of Candida species. Iran J Microbiol. 2016;8(6):410-7. PMID 28491253.
45. de Sousa LVNF, Santos VL, de Souza Monteiro A, Dias-Souza MV, Marques SG, de Faria ES, Assunção EAO, Dos Santos SG, Zonis JM, de Alvarenga DG, de Holanda RA, de Sousa JG, Dos Santos KV, Stoianoff MAR. Isolation and identification of Candida species in patients with orogastric cancer: susceptibility to antifungal drugs, attributes of virulence *in vitro* and immune response phenotype. BMC Infect Dis. 2016;16:86. doi: 10.1186/s12879-016-1431-4, PMID 26905729.
46. Liu Y, Wang W, Yan H, Wang D, Zhang M, Sun S. Anti-Candida activity of existing antibiotics and their derivatives when used alone or in combination with antifungals. Future Microbiol. 2019;14:899-915. doi: 10.2217/fmb-2019-0076, PMID 31394935.
47. Krcmery V, Barnes AJ. . HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/12014897/" Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance. J Hosp Infect. 2002; 50(4):243-60. doi: 10.1053/jhin.2001.1151, PMID 12014897
48. Azevedo MM, Teixeira-Santos R, Silva AP, Cruz L, Ricardo E, Pina-Vaz C, Rodrigues AG. The effect of antibacterial and non-antibacterial compounds alone or associated with antifugals upon fungi. Front Microbiol. 2015;6:669. doi: 10.3389/fmicb.2015.00669, PMID 26191055.
49. Sobel JD. HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/26164695/" Recurrent vulvovaginal candidiasis. Am J Obstet Gynecol. 2016; 214(1):15-21. doi: 10.1016/j.ajog.2015.06.067, PMID 26164695
50. Martino JL, Vermund SH. Vaginal douching: Evidence for risks or benefits to women's health. Epidemiol Rev. 2002;24(2):109-24. doi: 10.1093/epirev/mxf004, PMID 12762087.
51. Palmeira-de-Oliveira R, Palmeira-de-Oliveira A, Martinez-de-Oliveira J. New strategies for local treatment of vaginal infections. Adv Drug Deliv Rev. 2015;92:105-22. doi: 10.1016/j.addr.2015.06.008, PMID 26144995.
52. Machado D, Castro J, Palmeira-de-Oliveira A, Martinez-de-Oliveira J, Cerca N. Bacterial vaginosis biofilms: Challenges to current therapies and emerging solutions. Front Microbiol. 2015;6:1528. doi: 10.3389/fmicb.2015.01528, PMID 26834706.
53. Scholes D, Daling JR, Stergachis A, Weiss NS, Wang SP, Grayston JT. Vaginal douching as a risk factor for acute pelvic inflammatory disease. Obstet Gynecol. 1993;81(4):601-6. PMID 8459976.
54. Tebbets B, Yu Z, Stewart D, Zhao LX, Jiang Y, Xu LH, Andes D, Shen B, Klein B. Identification of antifungal natural products via *Saccharomyces cerevisiae* bioassay: Insights into macrotetrolide drug spectrum, potency and mode of action. Med Mycol. 2013;51(3):280-9. doi: 10.3109/13693786.2012.710917, PMID 22928922.
55. Branco P, Francisco D, Chambon C, Hébraud M, Arneborg N, Almeida MG, Caldeira J, Albergaria H. Identification of novel GAPDH-derived antimicrobial peptides secreted by *Saccharomyces cerevisiae* and involved in wine microbial interactions. Appl Microbiol Biotechnol. 2014;98(2):843-53. doi: 10.1007/s00253-013-5411-y, PMID 24292082.
56. Dubash T, Gupta S, Prakash PY, Bairy I. Isolation of Yeasts from Various Food Products and Detection of Killer Toxin Activity *In vitro*. J Sci Res. 2010;2(2):407-11. doi: 10.3329/jsr.v2i2.4159.
57. Ali MAE, Abdel-Fatah OM, Janson JC, Elshafei AM. Antimicrobial potential of Saccharomyces boulardii extracts and fractions. J Appl Sci Res. 2012;8(8):4537-43.
58. Sulistya Dewi ER, Legowo AM, Izzati M, Purwanto P. Kinetic growth of *Saccharomyces cerevisiae* in non-dairy creamer wastewater medium. Environ Stud. 2016;2(1):5.
59. Branco P, Francisco D, Monteiro M, Almeida MG, Caldeira J, Arneborg N, Prista C, Albergaria H. Antimicrobial properties and death-inducing mechanisms of saccharomycin, a biocide secreted by *Saccharomyces cerevisiae*. Appl Microbiol Biotechnol. 2017;101(1):159-71. doi: 10.1007/s00253-016-7755-6, PMID 27502415.
60. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 26th ed. CLSI supplement M100S. Wayne, PA: Clinical and Laboratory Standards Institute; 2016.
61. Development of *in vitro* susceptibility testing criteria and quality control parameters. 4th ed. This guideline discusses the necessary and recommended data for the selection of appropriate interpretive criteria and quality control ranges for antimicrobial agents; 2016.

Cite this article: Fatima D, Karima B. Antimicrobial Activity of *Saccharomyces cerevisiae* Against *Candida* spp. Associated to Vulvovaginal Candidiasis. Asian J Biol Life Sci. 2022;11(1):61-9.